Psilocybin Induces Lasting Changes in Brain Entropy and Neural Connectivity

A single high dose of psilocybin, the psychoactive compound found in “magic mushrooms,” produces measurable changes in brain activity and neural structure that persist for at least one month, according to research published in Nature Communications. The study, conducted by researchers at UC San Francisco and Imperial College London, indicates that these changes correlate with improved emotional well-being and psychological insight in healthy adults.

Brain Entropy and the Psychedelic Experience

The research focused on “brain entropy,” a metric used by neuroscientists to quantify the complexity and unpredictability of neural activity. According to the study, a high dose of psilocybin—specifically 25 mg—triggers a significant, temporary increase in this entropy. Senior author Robin Carhart-Harris, PhD, the Ralph Metzner Distinguished Professor of Neurology at UCSF, notes that this “psyche-revealing” state allows the brain to process a broader range of information than it does under normal conditions.

Data collected via electroencephalography (EEG) showed that participants who experienced the largest spikes in brain entropy during the acute phase of the psilocybin experience reported the greatest levels of emotional insight the following day. This insight, in turn, served as a predictor for improved self-reported well-being four weeks after the session.

Structural Brain Changes Observed After One Month

Beyond immediate shifts in electrical activity, the research team identified structural changes in the brain one month after the high-dose session. Using diffusion tensor imaging (DTI)—a technique that maps the movement of water molecules along neural pathways—researchers observed increased density and integrity in white matter tracts.

This finding is notable because it runs counter to the typical patterns of neural degradation often associated with aging. While the researchers emphasize that the long-term implications of these structural changes require further study, the results provide evidence that psilocybin may facilitate lasting physical reorganization within the brain.

Study Methodology and Comparison

The study involved 28 healthy volunteers with no history of psychedelic use or diagnosed mental health conditions. By using a controlled, two-stage experimental design, researchers were able to establish a clear baseline for comparison:

* Placebo Phase: Participants were administered 1 mg of psilocybin, treated as a placebo dose. Researchers monitored participants using EEG, fMRI, and DTI.
* Active Phase: After several weeks, the same participants received a 25 mg dose of psilocybin.
* Assessment: The team conducted longitudinal follow-ups at two weeks and four weeks post-dose, measuring cognitive flexibility, psychological insight, and well-being.

Participants demonstrated significant improvements in cognitive flexibility—the ability to adapt thinking to changing information—one month after the 25 mg dose compared to the placebo control.

Clinical Implications for Mental Health Therapy

These findings offer a mechanistic explanation for why psilocybin-assisted therapy has shown promise in treating conditions such as depression, anxiety, and addiction. According to first author Taylor Lyons, PhD, of Imperial College London, the substance appears to “loosen up” stereotyped, rigid patterns of brain activity. By disrupting these entrenched neural pathways, the treatment may provide individuals with the cognitive flexibility necessary to revise negative thought patterns.

The researchers suggest that future clinical applications could involve identifying specific dosages that maximize this entropic effect to foster therapeutic insight while minimizing potential discomfort from overly intense experiences. The study was funded by philanthropic donations to the Centre for Psychedelic Research at Imperial College London, the Alex Mosley Charitable Trust, the Beckley Foundation, and the UCSF Neuroscape Psychedelics Division.